In vitro antibacterial activity and in vivo efficacy of hydrated clays on Mycobacterium ulcerans growth

BMC Complementary and Alternative Medicine
Sarojini Adusumilli, Shelley E Haydel

Abstract

Buruli ulcer, caused by Mycobacterium ulcerans, is a localized skin lesion that can progress to extensive ulceration and necrosis if left untreated. Unpublished studies of hydrated clays for therapeutic, topical treatment of Buruli ulcer suggest that specific clay mineral products may have beneficial effects on wound healing. In this study, we evaluated the in vitro antibacterial activity of a panel of clay mixtures and their derivative leachates against M. ulcerans and assessed the in vivo efficacy of topically-applied, hydrated clays on Buruli ulcer progression in mice infected with M. ulcerans. M. ulcerans 1615 was incubated with 10% suspensions of CB07, CB08, CB09, CB10, and BY07 clay mixtures, and survival was determined over 28 days. For animal experiments, we examined the effect of topical hydrated clay therapy on Buruli ulcer progression in vivo in mouse tails subcutaneously infected with M. ulcerans 1615. The CB07, CB08, and CB09 clays exhibited bactericidal activity against M. ulcerans after 7, 14, 21, and 28 days of incubation. In contrast, clay leachates exhibited inhibitory, bacteriostatic effects on M. ulcerans growth in vitro. After establishing an ulcerative M. ulcerans infection for three months, ulcerated regi...Continue Reading

References

Sep 1, 1974·The American Journal of Tropical Medicine and Hygiene·W M MeyersD H Connor
Aug 6, 1998·Transactions of the Royal Society of Tropical Medicine and Hygiene·O AdjeiA Asiedu
Sep 29, 1999·Lancet·T S van der WerfK Asiedu
Jul 27, 2004·Antimicrobial Agents and Chemotherapy·R PhillipsA H J Kolk
Apr 21, 2005·PLoS Medicine·Paul D R JohnsonKingsley Asiedu
Apr 25, 2006·The Lancet Infectious Diseases·Vinciane SizaireFrançoise Portaels
Jun 7, 2006·Lancet·Mark Wansbrough-Jones, Richard Phillips
Apr 14, 2009·Clinics in Dermatology·Françoise PortaelsWayne M Meyers
Oct 24, 2009·The Lancet Infectious Diseases·Manuel T SilvaJorge Pedrosa
Nov 28, 2009·Current Medicinal Chemistry·M BechtleT Efferth
Sep 14, 2010·Microbes and Infection·Denise BambergerThomas Efferth
Dec 15, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Annick ChautyBaohong Ji
Nov 4, 2011·Human Vaccines·Thorbjorg Einarsdottir, Kris Huygen
Dec 14, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Willemien A NienhuisTjip S van der Werf
Dec 4, 2014·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics

❮ Previous
Next ❯

Citations

Jul 2, 2020·Environmental Geochemistry and Health·Celso Figueiredo GomesEduardo Ferreira da Silva
Feb 19, 2021·Journal of Ethnobiology and Ethnomedicine·Izabela SpielvogelJarosław Proćków

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Buruli Ulcer

Buruli ulcer is a progressive disease of subcutaneous tissues caused by mycobacterium ulcerans. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

© 2021 Meta ULC. All rights reserved